
|Articles|August 19, 2014
- Immunotherapy (Issue 3)
- Volume 3
- Issue 1
The Management of Side Effects Associated With Immunotherapies
Author(s)Jedd D. Wolchok, MD, PhD
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the management of side effects associated with immunotherapies.
Advertisement
Jedd D. Wolchok, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the management of side effects associated with immunotherapies.
View more about managing side effects and the limitations of immunotherapies > >
Articles in this issue
over 11 years ago
A Brief History of Immunotherapyover 11 years ago
Better Biomarker Testing Needed in Immuno-Oncologyover 11 years ago
Autoimmunity and Limitations of Cancer Vaccinesover 11 years ago
The Next Wave in Immunotherapy: Combinationsover 11 years ago
Future Immune Checkpoint StrategiesAdvertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
2
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Giredestrant/Everolimus Improves PFS Across Subgroups After CDK4/6i in ER+/HER2– Breast Cancer
5









































